Hoth Therapeutics Bolsters Oncology Pipeline with New U.S. Patent for HT-KIT Platform

Patent Award Establishes Robust Foundation for HT-KIT Platform

Hoth Therapeutics has received a Notice of Allowance from the U.S. Patent and Trademark Office for its HT-KIT oncology platform. The new patent covers composition-of-matter and methods focusing on antisense oligomers designed to target pre-mRNA splicing in MS4A6A—ultimately reducing surface expression of the high-affinity IgE receptor (FceRI), a key driver in mast cell activation and tumor biology.

What sets this patent apart is its scope: it includes both the novel chemical composition of the lead antisense oligomer (SEQ ID NO: 22) and pharmaceutical formulations that support a defensible, multi-layered intellectual property strategy for Hoth’s HT-KIT pipeline. The differentiated mechanism, involving exon-skipping of MS4A6A pre-mRNA, distinguishes it from antihistamine and anti-IgE antibody approaches, providing a potential edge in targeting diseases upstream of histamine release.

IP Coverage Enables Multiple Indications and Future Combinations

The allowed claims extend to a broad set of mast cell-driven diseases—ranging from asthma and atopic dermatitis to rare disorders like mastocytosis and mast cell tumors. The application also supports combination strategies, potentially pairing HT-KIT’s oligomers with those targeting other elements of mast cell signaling (such as FceRI via MS4A2 pre-mRNA), opening doors for future dual-target therapies.

Management Sees Validation and Strategic Opportunity Ahead

Robb Knie, Hoth’s CEO, emphasized that the patent validates years of scientific development and deepens the company’s competitive moat in mast cell-targeted treatments. The next major step for HT-KIT is an IND submission expected in 2026, with first-in-human studies on the horizon.

Biotech Subsidiary May Accelerate Platform Growth

Hoth plans to operate its biotechnology assets, including HT-KIT, within a standalone subsidiary. This structure aims to optimize management, preserve IP value for shareholders, and give the parent company space to explore emerging technology opportunities, notably in AI semiconductor infrastructure and advanced computing via its Rocket One, Inc. business.

Stock Snapshot and Key Platform Milestones

Key Takeaways for Investors

This patent win expands Hoth Therapeutics’ competitive position with a novel technology—one that addresses mast cell signaling at a critical mechanistic node. As the company prepares for regulatory submissions and potential clinical trials, its strategic biotech realignment and broad indication coverage may offer multiple catalysts for future growth. While development timelines remain ahead, the foundational patent could help attract additional partners or investors as the HT-KIT program advances toward human studies.

For more details about upcoming milestones or to access the complete press release, visit Hoth Therapeutics’ investor relations site.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI